List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 140 studies with search of:   "Exanthema"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Terminated A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
Conditions: Rash;   Non-Small-Cell Lung Cancer
Interventions: Drug: ACZONE (dapsone) Gel, 5%;   Drug: Vehicle Control
2 Recruiting Regulatory T Cells (Tregs) in Polymorphic Light Eruption
Conditions: Polymorphic Light Eruption;   Psoriasis;   Atopic Eczema
Intervention:
3 Not yet recruiting Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
Condition: Rash
Intervention: Drug: minocycline; Lotion (clindamycin 2% /hydrocortisone 1%)
4 Completed Sunscreen and After-Sun-Lotion Protection in Polymorphic Light Eruption
Condition: Polymorphic Light Eruption
Interventions: Other: After-sun-lotion with DNA repair enzymes;   Other: SPF30 sunscreen;   Other: Placebo after-sun-lotion;   Other: Intervention: none (only UV)
5 Active, not recruiting Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Condition: Skin Rash
Intervention: Procedure: Skin Biopsy of Skin Rash Secondary to EGFRI Use
6 Completed Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash
Condition: Diaper Rash
Interventions: Other: Zinc Oxide Diaper Rash Ointment;   Other: Aloe Vera/Tocopherol/Zinc Oxide Cream
7 Recruiting Investigation of Southern Tick-Associated Rash Illness (STARI)
Condition: Southern Tick-Associated Rash Illness
Intervention:
8 Recruiting Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
Condition: Polymorphic Light Eruption (PLE)
Intervention: Drug: CUV1647
9 Recruiting Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
Condition: EGFRI-Associated Rash
Interventions: Drug: Menadione;   Drug: Menadione
10 Recruiting Sorafenib-Induced Rash Treatment
Conditions: Hand-Foot Skin Reaction;   Rash
Interventions: Drug: urea 40% cream;   Drug: fluocinonide 0.05% cream;   Drug: tazarotene 0.1% cream;   Drug: bland emolient cream (Udderly smooth® Udder Cream)
11 Active, not recruiting STEPP: A Phase 2, Open-Label, Randomized Clinical Trial of Skin Toxicity Treatment in mCRC Subjects Receiving Panitumumab Concomitantly With Second-Line Irinotecan Based Chemotherapy
Conditions: Metastatic Colorectal Cancer;   Skin Rash;   Skin Toxicities;   Colon Cancer;   Colorectal Cancer
Intervention: Drug: Panitumumab
12 Active, not recruiting Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: tetracycline hydrochloride
13 Active, not recruiting Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
Conditions: Cancer-Related Problem/Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: canertinib dihydrochloride;   Drug: cetuximab;   Drug: erlotinib hydrochloride;   Drug: gefitinib;   Drug: matuzumab;   Drug: panitumumab;   Drug: titanium dioxide/zinc oxide sunscreen cream SPF 60
14 Terminated Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation
Condition: Skin Rash
Intervention: Other: Palifermin
15 Recruiting Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-Induced Rash
Condition: Non Small Cell Lung Cancer
Intervention: Drug: doxycycline
16 Recruiting MATER Study: A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: metronidazole actavis 1% topical cream
17 Recruiting Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer
Conditions: Cancer-Related Problem/Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: collagen/aloe vera/vitamin E/lidocaine topical hydrogel;   Procedure: observation;   Procedure: questionnaire administration
18 Recruiting A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: Doxycline
19 Recruiting A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: erlotinib [Tarceva];   Drug: gemcitabine
20 Not yet recruiting A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: fusidic acid [Verutex];   Drug: erythromycin [Eritex];   Drug: Fisiogel

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services